
Editas Medicine Investor Relations Material
Latest events

Strategy Update
Editas Medicine
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Editas Medicine Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Collaboration and other research and development revenues
Expenses by
Financials
Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Key slides for Editas Medicine Inc


Strategy Update
Editas Medicine Inc


Corporate Presentation
Editas Medicine Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
EDIT
Country
🇺🇸 United States